CONCORDBIO Q3 FY26 Guidance vs Delivery (CONCORDBIO Management Mirror)

Revenue & Growth Outlook

Lowered (Dec'25 Qtr): Management now anticipates FY26 revenue growth will remain below historical averages due to H1 challenges, shifting the timeline for "normalization" to FY27.

Reaffirmed (Dec'25 Qtr): Long-term baseline growth expectation remains ~18%, plus ~6% from injectables/CDMO, aiming for a ~25% CAGR once drivers are at full capacity (consistent with Sep'25 and Jun'25).

Modified (Dec'25 Qtr): Q4 FY26 is expected to be stronger than previous quarters due to recovering order momentum; this follows the Sep'25 expectation that H2 FY26 would exceed H2 FY25.

Sequential Evolution: In Jun'25, confidence in the 25% CAGR was absolute. By Sep'25, management emphasized a stronger H2 to drive growth. In Dec'25, they conceded FY26 will likely miss historical averages, pushing the full normalization and resumption of historical momentum to FY27.